Every 10-Q that Leap Therapeutics, Inc. (LPTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LPTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LPTX filings page.
Cypherpunk Technologies Inc. reported a Q1 2026 net loss of $77.2M, driven mainly by a $77.6M unrealized loss on the change in fair value of an embedded derivative tied to its Zcash (ZEC) digital asset receivable. Operating expenses fell sharply as research and development dropped to $0.2M from $12.9M after winding down clinical programs, while general and administrative costs rose to $4.7M on higher stock-based compensation and professional fees. Cash and cash equivalents were $6.7M and ZEC holdings were valued at $73.8M as of March 31, 2026, with an accumulated deficit of $539.7M. Management believes existing liquidity plus capacity under a $200M at-the-market program is sufficient to fund operations for at least 12 months, though a previously identified material weakness in internal control over financial reporting remains unremediated.
Cypherpunk Technologies Inc. (formerly Leap Therapeutics) filed its Q3 2025 10‑Q, reporting a smaller quarterly loss and a major strategic shift. The company posted a Q3 net loss of $3.3 million on operating expenses of $3.2 million, reflecting a significant year-over-year reduction in R&D and G&A. Cash and cash equivalents were $9.7 million at September 30, 2025, down from $47.2 million at year‑end.
After quarter‑end, Cypherpunk raised gross proceeds of $58.888 million in an October 2025 private placement of common stock, pre‑funded warrants, and common warrants, with approximate net proceeds of $57 million. The company disclosed that $7 million of the net proceeds will support operations, and it initiated a digital asset treasury strategy focused on Zcash (ZEC). Subsequent to quarter‑end, it purchased 203,775 ZEC for $50.0 million at a weighted average cost of $245.37 per token.
The company changed its name to Cypherpunk Technologies Inc. and its Nasdaq ticker to CYPH, while placing biotechnology activities into a wholly owned subsidiary (Leap Therapeutics, Inc.). A June 2025 restructuring wound down R&D programs and reduced headcount by about 75%, resulting in $4.5 million in year‑to‑date restructuring charges. Shares outstanding were 56,651,840 as of November 10, 2025.
Leap Therapeutics reported a difficult quarter marked by clinical progress on its lead asset but acute financial stress. Updated DeFianCe Part B data showed sirexatamab (DKN-01) produced a statistically significant benefit on overall response rate and progression-free survival in colorectal cancer patients with high DKK1, no prior anti‑VEGF therapy, or liver metastasis, with final study results being prepared for conference presentation.
Financially, the company had $18.13 million in cash and cash equivalents and $20.04 million total assets as of June 30, 2025, and reported a $32.08 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $499.45 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern, implemented a workforce reduction of approximately 75% and recorded $4.53 million of restructuring charges, and engaged Raymond James to explore strategic alternatives.